Japanese drugmaker Eisai is projecting strong commercial growth for its Alzheimer’s therapy Leqembi, signaling growing confidence in the global adoption of disease-modifying treatments for early Alzheimer’s disease.
According to the company’s latest investor presentation and financial outlook, Eisai expects Leqembi sales to reach 143.5 billion yen (around 900 million USD) during fiscal year 2026, representing nearly 63% growth over the previous year.
Leqembi, developed jointly with Biogen, has emerged as one of the most closely watched Alzheimer’s medicines globally because it targets amyloid-beta buildup in the brain and is designed to slow disease progression rather than only manage symptoms.
Eisai’s forecast suggests the company believes the drug is gradually overcoming the slow commercial rollout that affected its early launch phase. Increased physician familiarity, wider diagnostic infrastructure, expanding infusion capacity, and broader reimbursement coverage are now helping accelerate patient uptake in major markets including the United States, Japan, and China.
The company has also continued expanding regulatory approvals and treatment formats for Leqembi. The therapy is already approved in more than 50 countries and regions, while newer subcutaneous formulations and maintenance dosing options are under regulatory review in several markets.
Eisai previously reported that global Leqembi revenue reached 61.8 billion yen during the first nine months of fiscal 2025, with the United States contributing the largest share of sales.
Industry analysts believe Leqembi could become one of the first blockbuster Alzheimer’s medicines if adoption continues to improve. Eisai has earlier projected that annual sales may exceed 250 billion yen by fiscal 2027 as diagnosis rates improve and healthcare systems expand access to early Alzheimer’s treatment.
The growing momentum around Leqembi is also expected to benefit partners and collaborators including BioArctic, which could receive substantial royalty income tied to future sales growth.
